Search
forLearn
5 / 801 resultslearn TeraBond™ (Actera)
learn FC550
learn trimethicone
learn Selenium sulfide
Research
5 / 100 resultsresearch 丹蒽醌對人類惡性黑色素瘤細胞株(A375.S2)誘發細胞週期停滯及細胞凋亡之影響
Danthron from Rhubarb causes melanoma cells to stop growing and die.
research A Comprehensive Review on Nutrient Profile and Pharmacological Benefits of Musa paradisiaca
Bananas are highly nutritious and offer numerous health benefits, including anti-inflammatory and anticancer effects.
research The therapeutic, diagnostic, and prognostic values of extracellular vesicles (exosomes) in dermatology: A systematic review
Extracellular vesicles show potential in dermatology, but more research is needed for validation.
research Ancient botanicals and the skin: Defining dermatologic ethnophytoconvergence as a translational framework for pharmacognosy
Cross-cultural plant knowledge can improve skin treatments.
research Topical delivery of nanoemulsions for skin cancer treatment
Nanoemulsions can effectively treat skin cancer with fewer side effects.
Community Join
5 / 1000+ resultscommunity Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community Black market pp405? Title title
PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community SUBE3 for sale in the gray market?
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.